Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing ...

The blood-brain barrier border protects the brain by regulating the flow of molecules, peptides, and cells, but it also keeps out many therapeutics. Now, researchers have harnessed the power of a ...

Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing ...

REAL AD hints that blood markers can spot subtle cognitive decline. People who fluff a digital cognitive test have more ...

Immunoassay or Mass Spec? In secondary care, Lumipulse p-tau217 and MS p-tau217 or %p-tau217 are similarly accurate. In ...

Scientists see several important uses for staging. For example, it can steer people more precisely to appropriate treatments.

For one, microglia hovering around plaques—the type that express the most TREM2—reportedly become desensitized to stimulation ...

Evidence suggests that in Parkinson’s disease, a breakdown in lysosomal function allows lipids to build up within cells. Variants of the GBA1 gene, the strongest genetic risk factor for sporadic PD, ...

Some clinical trials for treatments that nip Alzheimer’s disease in the bud rely on recruiting carriers of autosomal-dominant mutations who will develop Alzheimer’s disease in a predictable fashion.

Tau PET correlates closely with cognitive decline in Alzheimer’s disease, making it a potential surrogate outcome measure. Yet in amyloid immunotherapy trials to date, this signal has not always ...